Paola Valsasina1, Maria A. Rocca1,2,3, Alessandro Meani1, Loredana Storelli1, Claudio Gobbi4,5, Chiara Zecca4,5, Frederik Barkhof6,7, Menno M Schoonheim8, Eva Strijbis7, Hugo Vrenken6,7, Antonio Gallo9, Alvino Bisecco9, Olga Ciccarelli10, Marios Yiannakas10, Alex Rovira11, Jaume Sastre-Garriga12, Jacqueline Palace13, Lucy Matthews13, Achim Gass14, Philipp Eisele14, Carsten Lukas15, Barbara Bellenberg15, Monica Margoni1, Paolo Preziosa1,2, and Massimo Filippi1,2,3,16,17
1Neuroimaging Research Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy, 2Neurology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy, 3Vita-Salute San Raffaele University, Milan, Italy, 4Neurology Clinic, MS Center/ Headache Center, Neurocenter of Southern Switzerland, Lugano, Switzerland, 5Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland, 6Radiology and Nuclear Medicine, MS Center Amsterdam, Amsterdam UMC, location Vumc, Amsterdam, Netherlands, 7Department of Neurology, MS Center Amsterdam, Amsterdam UMC, location Vumc, Amsterdam, Netherlands, 8Department of Anatomy and Neurosciences, MS Center Amsterdam, Amsterdam UMC, location Vumc, Amsterdam, Netherlands, 9Department of Advanced Medical and Surgical Sciences, and 3T MRI-Center, University of Campania “Luigi Vanvitelli”, Naples, Italy, 10NMR Research Unit, Queen Square MS Centre, Department of Neuroinflammation, UCL Institute of Neurology, London, United Kingdom, 11Section of Neuroradiology, Department of Radiology, Hospital Universitari Vall d'Hebron, Barcelona, Spain, 12Department of Neurology/Neuroimmunology, Multiple Sclerosis Centre of Catalonia, Hospital Universitari Vall d'Hebron, Barcelona, Spain, 13Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom, 14Department of Neurology, Universitätsmedizin Mannheim, University of Heidelberg, Mannheim, Germany, 15Institute of Neuroradiology, St. Josef Hospital, Ruhr-University Bochum, Bochum, Germany, 16Neurorehabilitation Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy, 17Neurophysiology Service, IRCCS San Raffaele Scientific Institute, Milan, Italy
Synopsis
Aim of this study was to evaluate
the independent role of brain and cervical cord damage in predicting 5-year
clinical disability worsening in a multicentre cohort of multiple sclerosis
patients. Results showed that cortical atrophy and spinal cord damage, together with baseline
disability and progressive disease phenotype, independently predicted 5-year
disability worsening (C-index=0.81). Older
age, higher clinical disability and cord lesion number independently predicted
conversion to a progressive disease phenotype (C-index=0.91). Focal spinal cord lesions and cortical atrophy had also a role in predicting clinically-relevant
disability milestones at 5 years.
Introduction
Multiple sclerosis (MS) is
a chronic, inflammatory and neurodegenerative disease of the central nervous
system, characterized by non-uniform clinical manifestations and a variable
disease progression [1]. In MS, the combined role of brain and spinal cord MRI
damage in predicting medium-term disease evolution still needs to be fully
elucidated. Against this background, aim of this study was to evaluate the
independent role of brain and cervical cord damage in predicting 5-year
clinical disability worsening in a multicentre cohort of MS patients, recruited
from 9 European sites. Methods
Baseline 3.0 T brain and cervical cord T2- and 3D T1-weighted MRI sequences
were acquired in 367 MS patients (326 relapse-onset, 41 progressive-onset) and 179
healthy controls [2]. Expanded
Disability Status Scale (EDSS) score was obtained at baseline and after a median
follow-up of 5.1 years (interquartile
range=4.5-5.5). Clinical
worsening was defined as an EDSS score increase ≥1.5 when baseline EDSS
was=0.0; an EDSS score increase ≥1.0 when baseline EDSS≤5.5; and an EDSS score
increase ≥0.5 when baseline EDSS was ≥6.0 [3]. Generalized linear mixed models
with L1-penalized variable selection identified the 5-year predictors of EDSS
worsening, secondary progressive (SP) MS conversion in relapsing-remitting (RR)
MS, and reaching EDSS=3.0, 4.0 and 6.0 milestones.Results
At follow-up, 120/367 (33%) MS patients
worsened clinically and 36/256 (14%) RRMS patients evolved to SPMS. MS patients reaching EDSS=3.0 at 5 year were
20 (out of 152, 13%), while MS patients reaching EDSS=4.0 at 5 years were 30 (out of 209, 14%), and patients reaching EDSS=6.0
at 5 years were 37 (out of 288, 13%). Significant predictors of clinical worsening at univariate analysis are
shown in Figure 1. At multivariate analysis, predictors of clinical worsening
were progressive- vs relapse-onset MS (standardized beta [b]=0.97), baseline EDSS score (b=0.41),
higher cord lesion number (b=0.41), lower normalized
cortical volume (b=-0.15) and cord
cross-sectional area (CSA) (b=-0.28) (C-index=0.81).
Significant predictors
of SPMS conversion at univariate analysis are shown in Figure 2. At multivariate
analysis, older age (b=0.86), higher EDSS score (b=1.40)
and cord lesion number (b=0.87) independently
predicted SPMS conversion (C-index=0.91). Significant univariate predictors of
reaching clinically-relevant EDSS milestones are shown in Figure 3. At multivariate analysis, predictors of reaching EDSS=3.0 (C-index=0.88)
were higher baseline EDSS score (b=1.49)
and cord lesion number (b=1.02), and lower normalized
cortical volume (b=-0.56). Baseline
age (b=0.30), higher EDSS score (b=2.03), higher cord lesion number (b=0.66),
and lower cord CSA (b=-0.41) predicted
EDSS=4.0 (C-index=0.92). Finally, higher baseline EDSS score (b=1.87) and higher cord lesion number (b=0.54)
predicted EDSS=6.0 (C-index=0.91). Discussion
Cortical atrophy and spinal cord damage
independently predicted 5-year disability worsening in MS. Focal spinal cord
lesions had a role in predicting both evolution to a progressive phenotype and
disability milestones. In addition, cord atrophy was one of the determinants of
locomotor disability.Conclusions
In MS patients, cortical atrophy and spinal cord
lesions and cord atrophy independently predicted 5-year disability worsening, reaching of EDSS milestones and SPMS conversion.
The combined assessment of brain and spinal cord damage may better identify MS
patients who will have disease progression after 5 years.Acknowledgements
No acknowledgement found.References
[1] Filippi M, Bar-Or
A, Piehl F, Preziosa P, Solari A, Vukusic S, Rocca MA. Multiple sclerosis. Nat
Rev Dis Primers 2018; 4(1):43.
[2] Rocca MA, Valsasina P, Meani A, Gobbi C,
Zecca C, Rovira À, Montalban X, Kearney H, Ciccarelli O, Matthews L, Palace J,
Gallo A, Bisecco A, Gass A, Eisele P, Lukas C, Bellenberg B, Barkhof F, Vrenken
H, Preziosa P, Comi G, Filippi M; MAGNIMS Study Group. Clinically relevant
cranio-caudal patterns of cervical cord atrophy evolution in MS. Neurology.
2019;93(20):e1852-e1866.
[3] Rocca MA, Valsasina P, Meani A, Pagani E,
Cordani C, Cervellin C, Filippi M. Network Damage Predicts Clinical Worsening
in Multiple Sclerosis: A 6.4-Year Study. Neurol Neuroimmunol Neuroinflamm.
2021;21;8(4):e1006.